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The intent of this article is to inform cardiology community with the aims and design of the
open, randomized multicentric study comparing the effect of two regimens of combined
immunosuppressive therapy with prednisone and azathioprine in the treatment of patients
suffering from inﬂammatory cardiomyopathy with biopsy proven presence of myocardial
inﬂammation and negative PCR ﬁndings for infectious cardiotropic agents. The authors of
this study encourage cardiologists to active participation in this research project whose
results may signiﬁcantly contribute to improvement of the therapy of patients with
inﬂammatory cardiomyopathy.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
.1. Introduction
Dilated cardiomyopathy (DCM) is a serious disease and repre-
sents the most common cause of heart failure in the young.ch Society of Cardiology.
Cardiovascular Diseases
, 656 91 Brno, Czech Repu
í).During their life, about 50% of patients with DCM progress into
the terminal stage of heart failure treatable only by cardiac
transplantation. Patients with DCM represent approximately
half of all heart transplants performed worldwide [1].Published by Elsevier Urban & Partner Sp.z o.o. All rights reserved.
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c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 7 5 – e 4 7 8e476There are numerous possible causes of DCM that may
affect heart muscle either primarily or secondarily as a part of
systemic disease. About 20–30% of primary DCM cases are
caused genetically, with mutations in genes encoding cytos-
keletal proteins being the most frequent [2]. In patients
without obvious family history of DCM, a causal relationship
with viral or other infectious agent-induced inﬂammation of
the myocardium (i.e. myocarditis) is often considered [3].
Therefore, myocarditis might be viewed as the most common
cause of non-familial DCM. The clinical presentation of the
myocardial infection is variable, ranging from completely
asymptomatic course to severe heart failure or sudden
cardiac death. In more than half of patients with acute
myocarditis, a gradual complete normalization of initially
depressed left ventricular (LV) function occurs. In the remain-
ing cases, LV systolic dysfunction persists and DCM develops.
When endomyocardial biopsy (EMB) is performed, the pre-
sence of chronic organ-speciﬁc autoimmune inﬂammation
and/or the persistence of viral or other infectious agent's
genome may be detected in many cases by immunohistolo-
gical methods and polymerase chain reaction (PCR) techni-
que, respectively. Such LV systolic dysfunction with biopsy
proven presence of inﬂammatory inﬁltration with or without
persistence of infectious agent is called inﬂammatory cardi-
omyopathy (ICM); an isolated evidence of viral genome in the
myocardium of DCM-subjects is then referred to by several
authors as chronic viral heart disease [4,5].
Treatment of ICM has been the subject of intense research
for several years. In addition to standard heart failure medica-
tion that is based on ACE inhibitors, betablockers, aldosterone
antagonists and diuretics [6], a therapy tailored to the complex
EMB diagnostics may be offered to affected individuals. Such
speciﬁc therapy aims either to reduce or completely eliminate
the presence of a persistent infectious agent, or to suppress
chronic autoimmune myocardial inﬂammation. The presence
of Borrelia burgdorferi or any bacterial agents in the myocardium
is viewed as a clear indication for antibiotic therapy [7]. When
chronic viral heart disease with EMB proven persistence of viral
genome is diagnosed, immunomodulatory therapy with
interferon-beta has been tested [8]. In this context, the impor-
tance of viral load and viral replication assessment have been
intensively studied [9].
Most of the evidence on the effectiveness are currently
available for speciﬁc therapy of ICM with EMB proven presence
of myocardial inﬂammation but negative PCR results. The data
arise from two clinical studies that demonstrated a positive
effect of combined immunosuppresive therapy. Wojnicz et al.
studied 84 patients with DCM and symptoms of heart failure
lasting more than six months, in whom EMB demonstrated
chronic myocardial inﬂammation deﬁned by increased HLA
antigens expression (the presence of viral genome in the
myocardium was not evaluated) [10]. Patients were randomized
to placebo or immunosuppressive therapy with steroids and
azathioprine added to conventional heart failure therapy. Pre-
dnisone was given for 90 days, with initial dose of 1 mg/kg/day
for ﬁrst 12 days with subsequent tapering of every ﬁve days by
5mg/day until reaching themaintenance dose of 0.2 mg/kg/day.
Azathioprine was given at a dose of 1mg/kg/day for a total of
100 days. After two years, there were no signiﬁcant differences
in the primary end-point comprising a composite of death,heart transplantation, and hospital readmission between the
two study groups. However, signiﬁcant differences were found
in the secondary end-points. LV ejection fraction, volumes and
diameters signiﬁcantly improved in patients treated with
immunosuppression compared with the placebo group after
three months and this difference persisted also at one and two
years follow-up. Moreover, heart failure symptoms assessed by
NYHA classiﬁcation also signiﬁcantly improved in the immu-
nosuppression group compared with the placebo group at one
and two years follow-up.
In the second trial, which was randomized, double-blind
TIMIC study, Frustaci et al. followed 85 patients with heart
failure symptoms lasting more than six months in whom PCR-
viral negative ICM was diagnosed by EMB with myocardial
inﬂammation deﬁned by the presence of 414 inﬁltrating
leukocytes (LCA + cells)/mm2 and/or 47 CD3-positive lympho-
cytes/mm2 [11]. These patients were also randomized to placebo
or immunosuppressive therapy with steroids and azathioprine
added to conventional heart failure therapy. Prednisone was
given at the initial dose of 1 mg/kg/day for four weeks, with
subsequent maintenance dose of 0.33 mg/kg/day for ﬁve
months. Azathioprine was given at the dose of 2 mg/kg/day
for six months. At six months follow-up, a statistically signiﬁ-
cant difference in the primary end-point was observed. In
patients treated with combined immunosuppressive therapy,
LV ejection fraction, volumes and diameters signiﬁcantly
improved compared with baseline. On the contrary, a signiﬁcant
worsening of LV parameters was found in the placebo group.
In summary, both so far published randomized, placebo-
controlled studies investigating the usefulness of combined
immunosuppressive therapy in patients with ICM demon-
strated positive effect of this treatment on LV systolic function
as well as on LV diameters and volumes. However, different
schemes of immunosuppressive therapy were used both in
terms of the dosage of individual drugs as well as of the total
length of their administration. Both studies were also focused
on the effect of immunosuppressive therapy in patients with a
history of ICM lasting at least six months, i.e. they did not
include individuals with recent onset of heart failure due to
newly diagnosed ICM. One may speculate that the positive
effect of immunosuppressive therapy on LV morphology and
function might be more pronounced if such anti-inﬂammatory
therapy was administered earlier when LV remodeling asso-
ciated with maladaptive myocyte hypertrophy, necrosis, apop-
tosis and interstitial ﬁbrosis was at its beginning [12].2. The aims and design of the
CZECH-ICIT study
The purpose of the open, randomized, multicentric CZECH-
ICIT study is based on the results of the two above-
mentioned randomized studies that demonstrated positive
effect of combined immunosuppressive therapy on LV mor-
phology and function in patients with ICM [10,11]. As already
mentioned, both studies differed in the dosage and in total
time of immunosuppressive drugs administration. Further-
more, they included only patients with heart failure
symptoms lasting at least six months.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 7 5 – e 4 7 8 e477The aim of the CZECH-ICIT trial is head to head compar-
ison of the effect of two dosing regimens of combined
immunosuppresive therapy used in previous studies in
patients with ICM deﬁned by EMB established presence of
myocardial inﬂammation and negative PCR ﬁndings of infec-
tious cardiotropic agents, and comparison against conven-
tional heart failure therapy as well. Importantly, studied
individuals will not be only the patients with heart failure
symptoms LV systolic dysfunction lasting more than 6
months, as was the case in Wojnicz's study and TIMIC trial
[10,11], but also the patients with shorter history of heart
failure (i.e. less than 6 months).
The study population consists of patients of both genders
aged 18–65 years, with LV systolic dysfunction deﬁned by
ejection fraction r40% (that lasts either at least 2 weeks to 6
months since heart failure symptoms appeared or more than
6 months since heart failure symptoms appeared in time of
randomization), heart failure symptoms NYHA class II–IV,
with positive EMB immunohistochemical ﬁndings indicating
the presence of myocardial inﬂammation and the absence of
infectious agents deﬁned as negative results of PCR analysis
of EMB samples. The positivity of the EMB immunohisto-
chemical analysis is deﬁned as the presence of more than 7
CD3 positive lymphocytes/mm2 and/or more than 14 inﬁltrat-
ing leukocytes (LCA positive cells/mm2) in one EMB sample.Table 1 – Inclusion and exclusion criteria of the CZECH-ICIT st
Inclusion criteria of the CZECH-ICIT study
1. Men and women aged 18–65 years.
2. LV systolic dysfunction deﬁned by ejection r40% lasting at least 2 wee
heart failure symptoms.
3. Symptoms of heart failure ZNYHA class II.
4. Positive immunohistochemistry of the EMB demonstrating myocardial
inﬁltrating leukocytes/LCA positive cells/mm2) with negative PCR resu
5. Negative pregnancy test in women of childbearing age.
6. Effective form of contraception in women of childbearing age.
Exclusion criteria of the CZECH-ICIT study
1. The presence of coronary artery disease deﬁned by the stenosis of an
history of myocardial infarction and/or percutaneous or surgical myo
during a 2-year period prior to randomization to the study.
2. Permanent pacing, including cardiac resynchronization therapy.
3. The presence of uncorrected sustained supraventricular arrhythmia wi
4. The presence of prolonged uncorrected arterial hypertension deﬁned
4110 mmHg for more than 3 months.
5. The presence of hemodynamically signiﬁcant primary valvulopathy a
hemodynamically insigniﬁcant atrial septal defect.
6. Status after valve replacement, reconstructive surgery or intervention
7. Cytostatic therapy or radiotherapy in the past medical history.
8. Alcoholism deﬁned by ethanol intake 490 g/day.
9. The presence of uncorrected endocrine or metabolite disorder.
10. Pregnancy and lactation.
11. Known hypersensitivity to the investigational drugs.
12. Any contraindication to the use of immunosuppressive therapy, inclu
compensation, osteoporosis, ﬂorid ulcer disease of stomach and/or du
malignancy within last ﬁve years, proven immunodeﬁciency, renal or
AST levels elevated 43 above the upper normal range), leukocytop
(number of platelets less than 100 109 l1), anemia (concentration ofThe inclusion and exclusion criteria of the CZECH-ICIT study
are summarized in Table 1.
The study consists of two substudies, CZECH-ICIT 1 and 2,
whose primary and secondary end-point are the same. In the
substudy CZECH-ICIT 1, the individuals with biopsy-proven ICM
with persisting LV systolic dysfunction deﬁned by LV ejection
fraction r40% and with symptoms of heart failure at least
NYHA class II lasting 2 weeks to 6 months, who have been
treated for at least 2 weeks with standard pharmacological
treatment of heart failure will be enrolled. In the substudy
CZECH-ICIT 2, the patients with biopsy-proven ICM with per-
sisting LV systolic dysfunction deﬁned by LV ejection fraction
r40% and with symptoms of heart failure at least NYHA class II
lasting more than 6 months will be enrolled.
Each substudy will start with phase A, in which the
patients will be randomized into 3 arms. In the two treatment
arms the subjects will receive immunosuppressive medica-
tion in two different dosing regimens together with the
established standard medical treatment of heart failure.
Individuals randomized into the third arm will be treated
only by established standard pharmacological treatment of
heart failure according to current guidelines. Therefore, it will
be possible to compare the effect of two immunosuppressive
regimens added to conventional heart failure medication
against standard heart failure therapy itself in patients withudy.
ks to maximally 6 months/or 46 months since the ﬁrst appearance of
inﬂammation (47CD3 positive lymphocytes/mm2 and/or 414
lts excluding the presence of infectious agent.
y coronary artery vessel 450% detected by coronary angiography, oral
cardial revascularization. Coronary angiography must be performed
th ventricular rate4120 min1, lasting more than 1 week prior to EMB.
by systolic blood pressure 4180 mmHg a/or diastolic blood pressure
nd congenital heart disease except from patent foramen ovale and
al procedure on any heart valve.
ding untreated systemic infection, difﬁculties with diabetes mellitus
odenum, poorly controlled arterial hypertension, treatment of
hepatic insufﬁciency (serum creatinine level 4200 μmol/l; ALT and/or
enia (number of leukocytes less than 4109 l1) thrombocytopenia
hemoglobin less than 100 g/l).
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 7 5 – e 4 7 8e478ICM lasting less than 6 months (substudy CZECH-ICIT 1) and
more than 6 months (substudy CZECH-ICIT 2), respectively.
If statistical analysis reveals signiﬁcant positive effect of
combined immunosuppressive therapy in both dosing regi-
mens, the phase B of one or both substudies will follow, in
which the effect of two immunosuppressive regiments
(added to conventional heart failure therapy) among them-
selves will be assessed.
The primary end-point of phase A of both substudies is to
assess the change in LV ejection fraction in patients with ICM
treated with two different dosing regimens of combined immu-
nosuppressive therapy given on top of the standard medical
therapy for chronic heart failure compared to standard heart
failure medical therapy alone. The primary end-point of phase B
of both substudies is then to compare the change in LV ejection
fraction in patients with ICM treated with two different dosing
regimens of combined immunosuppressive therapy given on
top of the standard medical therapy for chronic heart failure.
Primary end-points will be evaluated 12 months after initiation
of combined immunosuppressive therapy.
Secondary end-points of both substudies include: the eva-
luation of the changes of LV diastolic and systolic diameters; the
changes in NYHA heart failure classiﬁcation; the occurrence of
the combined end-point consisting of cardiovascular mortality,
heart transplantation, hospitalization for heart failure, success-
fully resuscitated cardiac arrest and adequate ICD therapy for
ventricular tachycardia or ﬁbrillation; all-cause mortality; the
changes in number of inﬁltrating inﬂammatory cells in baseline
and control EMB samples; tolerance and incidence of adverse
events between both immunosuppressive regimens.
The clinical trial CZECH-ICIT is conducted in the framework
of the International Clinical Research Centre in Brno and
represents a joint research project of the Department of
Cardiovascular Diseases, St. Anne's University Hospital – Inter-
national Clinical Research Center and Masaryk University in
Brno and 2nd Department of Medicine-Department of Cardio-
vascular Medicine of the General University Hospital in Prague.
The study protocol was approved by the State Institute for Drug
Control as well as by Ethical Committees of both hospitals. The
CZECH-ICIT study is registered both in the European Clinical
Trials Database (EudraCT) with a number 2012-002828-33 and in
the registry of clinical trials http://ClinicalTrials.gov. Recruit-
ment of the patients was initiated in January 2013. The
participation of other cardiology centers that are interested in-
biopsy based diagnosis and treatment of ICM is welcome,
including foreign medical institutions. The authors of the
CZECH-ICIT trial thus cordially invite active participation by
Czech as well as foreign cardiologists in this research project
whose results may signiﬁcantly affect future therapy of ICM. In
case of interest for participation in the CZECH-ICIT trial or
consultation about suitability of the patient for inclusion into
this study, please contact one of the ﬁrst co-authors of this
article T. Paleček (Tomas.Palecek@lf1.cuni.cz) and/or J. Krejčí
(jan.krejci@fnusa.cz), who are also the principle co-investigators
of the CZECH-ICIT trial.Acknowledgments
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